Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Two-hundred sequential Aspergillus fumigatus isolates recovered from 26 immunocompromised patients with invasive aspergillosis or bronchial colonization were tested for their in vitro susceptibility to posaconazole, itraconazole, voriconazole, terbinafine and amphotericin B. Twenty-one patients were treated with amphotericin B and/or itraconazole. Antifungal susceptibilities of the isolates recovered before treatment were not significantly different from those of isolates recovered after the onset of antifungal therapy. The highest MICs were 0.125, 0.5, 0.5, 1 and 1 microg ml(-1) for posaconazole, itraconazole, voriconazole, terbinafine and amphotericin B, respectively. It is concluded that the emergence of resistance in A. fumigatus during antifungal therapy with amphotericin B or itraconazole is an uncommon phenomenon.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844 · cited 2×
“Voriconazole has been shown to be efficacious in treating invasive aspergillosis in patients (Denning et al., 2002) and preliminary data have shown that posaconazole was efficacious as salvage treatment of invasive aspergillosis in patients refractory to, or intolerant of, standard antifungal therapies (Hachem et al.”
ResultResistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences
Sanglard, D., & Odds, F. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00181-0 · Cited by 784
Espinel-Ingroff, A., Bartlett, M., Bowden, R., Chin, N. X., Cooper, C., Fothergill, A., McGinnis, M. R., Menezes, P., Messer, S. A., Nelson, P. W., et al. (1997) · Journal of Clinical Microbiology · doi:10.1128/jcm.35.1.139-143.1997 · Cited by 228 · cited 1×
“The spore suspensions were transferred to a sterile tube, turbidity wasmeasured spectrophotometrically at 530 nm and adjusted to an optical density ranging from 0.09 to 0.11 (80–82% transmittance), to yield an initial inoculum of 5 3 105 to 5 3 106 c.f.u. ml 1 (Espinel-Ingroff et al., 1997).”
MethodInfluential
Cited by
Aspergillus Infections in Transplant Recipients
Singh, N., & Paterson, D. L. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.44-69.2005 · Cited by 579
Regulatory circuitry governing fungal development, drug resistance, and disease.
Shapiro, R. S., Robbins, N., & Cowen, L. E. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00045-10 · Cited by 576
Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.
Cowen, L. E., & Steinbach, W. J. (2008) · Eukaryotic Cell · doi:10.1128/ec.00041-08 · Cited by 285
Da Silva Ferreira, M. E., Colombo, A. L., Paulsen, I., Ren, Q., Wortman, J., Huang, J., Goldman, M. H. S., & Goldman, G. H. (2005) · Medical Mycology · doi:10.1080/13693780400029114 · Cited by 158
“In another study [ 11 ], the same authors recovered 200 sequential A. fumigatus from 26 immunocompromised patients with invasive aspergillosis or bronchial colonization and tested them for their in vitro susceptibility to posaconazole, itraconazole, voriconazole, terbinafine and amphotericin B. Antifungal susceptibili…”
ResultDudakova, A., Spiess, B., Tangwattanachuleeporn, M., Sasse, C., Buchheidt, D., Weig, M., Groß, U., & Bader, O. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00095-16 · Cited by 113
Metadata
- Authors
- Dannaoui, E.
- Venue
- Journal of Medical Microbiology
- Publisher
- Microbiology Society
- Published
- 2004-02-01
- Volume
- 53
- Issue
- 2
- Pages
- 129-134
- ISSN
- 0022-2615 (ISSN-L)
- 1473-5644
- OpenAlex
- W2123852339
- Cited by
- 45
- References
- 3
- FWCI
- 2.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients. https://app.cochat.ai/papers/10.1099/jmm.0.05326-0
- The paper
- Dannaoui, E. (2004). Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients. Journal of Medical Microbiology. https://doi.org/10.1099/jmm.0.05326-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.